Biomass Sensors in iCELLis™ Fixed-Bed Reactors: Data on CHO and Vero Cells

Viral vaccines, monoclonal antibodies and glycosylated therapeutic proteins are usually produced by mammalian cells in bioreactors. Since fixed-bed bioreactors enable high volumetric yields, they have often been considered as a potential high-performance technology. However, one of the identified drawbacks of this technology is the difficulty to take samples from the reactor to assess cell density. To overcome this obstacle, we have made a comparison study between the use of different biomass probes and manual sampling and cell counting.